Exelixis, Inc. announced that its oncology drug, Cometriq (cabozantinib) has received
Breakthrough Therapy designation from the FDA as a potential treatment
for patients with advanced Renal Cell Carcinoma (RCC) who have received
one prior therapy.
Breakthrough
therapy designation from the FDA is expected to expedite the
development and review of drugs that are intended to treat serious
diseases and to provide access to patients as soon as possible.
Cometriq is already approved in the U.S. for the treatment of
progressive, metastatic Medullary Thyroid Cancer (MTC). Additionally, it
has been granted conditional approval in the EU for the treatment of
adult patients with progressive, unresectable locally advanced or
metastatic MTC.
No comments:
Post a Comment